I would counter that if RVX would sell out for $10 CDN or USD that a BP would have already snapped this company up. On a fully diluted basis $1.3B would seem like quite a discount given that early in the year management felt that just CVD, DM and CKD had a then current EV of $1.7B USD.  That was without FDA approval which according to Don has "added significant value to the program". All the other compounds in RVX would be obtained for free? Additionally if BP waits until BoM is successful they will be paying much more than double your $10 figure, go back and look at managements staged EV charts. Perhaps $10 as the upfront money in a CVR might do it. 

I think that some people feel that pharma having not visibly acted thus far means they are not interested. Personally I don't think we on the outside will know of any interest until a deal is done.